Our Mission

To promote animal health and welfare by developing and delivering new treatment solutions to veterinary medical practitioners. Responsiveness, clinical excellence, and innovation are key. We currently develop novel blood products for use in hemostasis and regenerative medicine.

Our History
Our Namesake

Our Mission

To promote animal health and welfare by developing and delivering new treatment solutions to veterinary medical practitioners. Responsiveness, clinical excellence, and innovation are key. We currently develop novel blood products for use in hemostasis and regenerative medicine.

Our History
Our Namesake

Slide Our History Formed in 2015, BodeVet, Inc. is a wholly owned subsidiary of Cellphire, Inc. BodeVet uses technology borrowed from Cellphire to develop veterinary medicines. Cellphire originally formed in 2006 to research innovative cell stabilization technologies. Cellphire applied this technology to blood platelets and created Thrombosomes®, a stable, platelet-derived product. Platelets naturally prevent bleeding in humans and in animals, but have a short (5 day) shelf life when removed from the body; platelet units are scarce. Unlike platelets, Thrombosomes® have a shelf life measured in years, and the potential to profoundly influence bleeding management.

Thrombosomes® were tested for safety and efficacy in canine and rabbit models. These results were provided to CVM (FDA) as Cellphire sought permission to commercialize stable, platelet-derived products for animals. BodeVet was formed to develop products for animals, and its first product, StablePlate RX(R), was launched at to on IVECCS in September 2017.' (StablePlate RX(R) should be formatted the same as it already is on the site). Although primarily focused on canine and equine conditions, BodeVet is also supporting work focused at endangered species (elephants, cheetah and rhinos). BodeVet’s team works closely with Cellphire’s to ensure its technologies are translated as effectively as possible. BodeVet is staffed and advised by world leaders in veterinary medicine.

Slide Our Namesake The Board, Officers and colleagues at BodeVet, Inc. commemorate our colleague Dr. Arthur P. Bode (b. 1953, d. 2016) by naming the company in his memory. Eminent in the field of platelet research, and a joy with whom to work, BodeVet is proud to be named after a visionary within our field. Dr. Bode spent 25 years in an academic setting focusing on the scientific investigation in platelet function and transfusion. After retiring as a full-time professor in Pathology from East Carolina University in 2009, and several years in a start-up company as Chief Science Officer for projects involving spray-dried plasma or lyophilized platelets, he joined BodeVet in early 2014. The BodeVet team strives towards maintaining the standard and scientific excellence that Art Bode exemplified. A gentleman and a scholar, he will be greatly missed.

Slide Our Namesake The Board, Officers and colleagues at BodeVet, Inc. commemorate our colleague Dr. Arthur P. Bode (b. 1953, d. 2016) by naming the company in his memory. Eminent in the field of platelet research, and a joy with whom to work, BodeVet is proud to be named after a visionary within our field. Dr. Bode spent 25 years in an academic setting focusing on the scientific investigation in platelet function and transfusion. After retiring as a full-time professor in Pathology from East Carolina University in 2009, and several years in a start-up company as Chief Science Officer for projects involving spray-dried plasma or lyophilized platelets, he joined BodeVet in early 2014. The BodeVet team strives towards maintaining the standard and scientific excellence that Art Bode exemplified. A gentleman and a scholar, he will be greatly missed.